New Zealand markets close in 13 minutes
  • NZX 50

    -35.31 (-0.30%)

    -0.0007 (-0.11%)

    -0.0005 (-0.08%)

    -9.90 (-0.12%)
  • ASX 200

    -9.60 (-0.12%)
  • OIL

    0.00 (0.00%)
  • GOLD

    -5.30 (-0.25%)

    +259.11 (+1.44%)
  • FTSE

    +52.48 (+0.69%)
  • Dow Jones

    +90.98 (+0.23%)
  • DAX

    +56.87 (+0.32%)
  • Hang Seng

    +8.76 (+0.05%)
  • NIKKEI 225

    +316.01 (+0.79%)

    -0.0690 (-0.08%)

Trastuzumab Biosimilars Global Market Report 2022: Focus on Product Launches by Major Players Shaping Industry

Company Logo
Company Logo

Global Trastuzumab Biosimilars Market

Global Trastuzumab Biosimilars Market
Global Trastuzumab Biosimilars Market

Dublin, Sept. 27, 2022 (GLOBE NEWSWIRE) -- The "Trastuzumab Biosimilars Global Market Report 2022: By Product, By Indication, By Distribution" report has been added to's offering.

The global trastuzumab biosimilars market is expected to grow from $2.08 billion in 2021 to $2.64 billion in 2022 at a compound annual growth rate (CAGR) of 27.1%. The market is expected to reach $6.90 billion in 2026 at a CAGR of 27.1%.

North America was the largest region in the trastuzumab biosimilar market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities.

According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the market.

The side effects of trastuzumab biosimilar are expected to limit the growth of the trastuzumab biosimilar market. The side effects of Herceptin (chemical name: Trastuzumab) include diarrhea, nausea, fever, heart problems, infection, cough, and rashes. Moreover, breast cancer studies reflect that the exposure of trastuzumab (Herceptin) therapy increased the rate of asymptomatic cardiac dysfunction in the two-year trastuzumab treatment from 4.6% to 8.1%. The rate of at least one patient experienced Grade-3 or higher, for treatment with trastuzumab is at 20.4% for two years, compared to 16.1% for one year of treatment. The side effects of trastuzumab have a negative impact on the trastuzumab biosimilar market.

Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers.

For instance, in December 2019, Biocon and Mylan launched Ogivri (trastuzumab-dkst), Trastuzumab Biosimilar in the USA. Mylan plans to offer Ogivri in 150 mg and 420mg strengths, increase access for the treatment of HER2-positive breast and gastric cancer.

In February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately $1,325 and $3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.

Markets Covered:
1) By Product: Ogivri; Herzuma; Ontruzant; Trazimera; Others
2) By Indication: Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Others
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy

Key Topics Covered:

1. Executive Summary

2. Trastuzumab Biosimilars Market Characteristics

3. Trastuzumab Biosimilars Market Trends And Strategies

4. Impact Of COVID-19 On Trastuzumab Biosimilars

5. Trastuzumab Biosimilars Market Size And Growth

6. Trastuzumab Biosimilars Market Segmentation

7. Trastuzumab Biosimilars Market Regional And Country Analysis

8. Asia-Pacific Trastuzumab Biosimilars Market

9. China Trastuzumab Biosimilars Market

10. India Trastuzumab Biosimilars Market

11. Japan Trastuzumab Biosimilars Market

12. Australia Trastuzumab Biosimilars Market

13. Indonesia Trastuzumab Biosimilars Market

14. South Korea Trastuzumab Biosimilars Market

15. Western Europe Trastuzumab Biosimilars Market

16. UK Trastuzumab Biosimilars Market

17. Germany Trastuzumab Biosimilars Market

18. France Trastuzumab Biosimilars Market

19. Eastern Europe Trastuzumab Biosimilars Market

20. Russia Trastuzumab Biosimilars Market

21. North America Trastuzumab Biosimilars Market

22. USA Trastuzumab Biosimilars Market

23. South America Trastuzumab Biosimilars Market

24. Brazil Trastuzumab Biosimilars Market

25. Middle East Trastuzumab Biosimilars Market

26. Africa Trastuzumab Biosimilars Market

27. Trastuzumab Biosimilars Market Competitive Landscape And Company Profiles

28. Trastuzumab Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Trastuzumab Biosimilars Market

30. Trastuzumab Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

Companies Mentioned

  • Amgen inc.

  • Pfizer inc.

  • Samsung Bioepis

  • Merck & Co.

  • Biocon Limited

  • Mylan inc.

  • BioXpress Therapeutics

  • Celltrion

  • Teva Pharmaceutical Industries Ltd.

  • EirGenix inc.

  • ALTEOGEN inc.

  • Apotex (Apobiologix)

  • AryoGen Pharmed


  • Prestige BioPharma (PBP)

  • PlantForm

  • Outlook Therapeutics (Oncobiologics)

  • Shanghai CP Guojian Pharmaceutical

  • Shanghai Henlius Biotech

  • Stada Arzneimittel

For more information about this report visit


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900